On March 29, it was disclosed at the 27th Chinese Medical Association Interventional Cardiology Conference and the 13th Chinese Chest Pain Center Conference (CCIF & CCPCC 2024) that the registration data for coronary intervention therapy in mainland China in 2023 reached 1.63 million (excluding cases from military hospitals), with a growth rate of 26.44%. Among them, Hebei Province, Beijing Municipality, Henan Province, Shandong Province, and Zhejiang Province ranked among the top five in terms of case numbers.
Huoyong (Provided by the Organizer)
Chairman of the Conference and Professor Huoyong from Peking University First Hospital stated that in the past 30 years, China's percutaneous coronary intervention (PCI) technology has made significant progress. In order to analyze the current status and development trends of coronary intervention treatment in China, the former Ministry of Health (now the National Health Commission) established a quality control system in 2009. All medical institutions nationwide report relevant data on coronary intervention treatment to this system. The statistics released this time fully reflect the good development trend of coronary intervention in China, demonstrating China's transition from a major player in intervention to a strong player.
In terms of quality control indicators, evaluations are mainly conducted from dimensions such as the number of stents/balloons used, the proportion of drug-coated balloon usage, surgical approach, surgical mortality rate, clinical diagnosis of PCI cases, and the ratio of PCI cases for ST-segment elevation myocardial infarction (STEMI) to direct PCI.
The results show that the average number of stents/drug-coated balloons in 2023 was 1.51, trending towards stability. Over the past five years (2019-2023), the proportion of drug-coated balloon usage has continuously increased, reaching 6.4%, 10.9%, 15%, 17.6%, and 18.5% respectively. Compared to other approaches such as femoral artery access, radial artery access has become the mainstream approach in the past decade. In terms of surgical mortality rate, there was a slight decrease in 2023 compared to 2022, at 0.36%. Clinical diagnosis of PCI cases, STEMI case numbers, and direct PCI case numbers were basically the same as in 2022.
Huoyong concluded that in 2023, the number of coronary intervention cases in mainland China grew rapidly, while the selection of coronary intervention technology indications, equipment usage, and clinical outcomes remained stable and of good quality. The proportion of direct PCI for STEMI has entered a plateau period after rapid growth, still lagging behind developed countries, and more efforts are needed to further improve it. The quantity and capability of county-level hospitals conducting coronary intervention treatment have both increased significantly.
